<DOC>
	<DOCNO>NCT02451930</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy combination necitumumab pembrolizumab participant stage IV non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study Combination Necitumumab ( LY3012211 ) Pembrolizumab ( MK3475 ) Participants With NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>The participant Stage IV NSCLC . Part A : NSCLC Stage IV ( type ) Part B : NSCLC Stage IV ( squamous nonsquamous ) Part C : NSCLC Stage IV Japanese participant ( squamous nonsquamous ) The participant must progress 1 platinumbased chemotherapy regimen Stage IV NSCLC . Prior therapy VEGF/VEGFR target agent permit . Prior neoadjuvant/adjuvant therapy permit . Prior treatment EGFRTKI ALK inhibitor mandatory participant NSCLC whose tumor EGFRactivating mutation ALK translocation , respectively . Measurable disease time study entry define Response Evaluation Criteria In Solid Tumors Version 1.1 ( RECIST 1.1 ) . The participant evaluable tumor tissue available biomarker analysis . The participant adequate organ function . Eastern Cooperative Oncology Group performance status ( ECOG PS ) score 01 . The participant currently enrol clinical trial involve investigational product nonapproved use drug device . Prior treatment antiPD1 , antiPDL1 , antiPDL2 monoclonal antibody . Have serious concomitant systemic disorder significant cardiac disease . The participant undergone major surgery receive anticancer monoclonal antibody therapy 30days prior study enrollment . The participant undergone chest irradiation within 2 week prior receive study treatment . The participant brain metastasis symptomatic . The participant history arterial thromboembolism event ( ATE ) venous thromboembolism event ( VTE ) within 3 month prior study enrollment . Participants history VTE beyond 3 month prior study enrollment enrol appropriately treat low molecular weight heparin . The participant know allergy / history hypersensitivity reaction treatment component , include ingredient use formulation necitumumab pembrolizumab , contraindication one administer treatment . The participant concurrent active malignancy . Previous history malignancy permit , provide participant free disease â‰¥3 year , exception adequately treat basal squamous cell carcinoma skin , preinvasive carcinoma cervix , cancer judgment investigator sponsor may affect interpretation result ( example , prostate , bladder ) . History interstitial lung disease , pneumonitis , autoimmune disease syndrome require steroid immunosuppressive agent . The participant active infection require systemic therapy , include active tuberculosis know history infection human immunodeficiency virus ( HIV 1/2 antibody ) , hepatitis B ( e.g. , HBsAg reactive ) and/or C virus ( e.g. , HCV RNA [ qualitative ] detect ) . The participant active autoimmune disease document history autoimmune disease , syndrome require systemic steroid immunosuppressive agent . The participant receive live vaccine within 30 day prior first dose trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>